PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead ...

As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...

IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its ...

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMNN-001 Phase 3 trial is ...

Assiduous planning and flexibility were the factors critical to the project’s success. Focusing on these factors enabled us to move at a rapid pace, engage in parallel ramp-up efforts, and devise ...

Shih is also an investigator at the Innovative Genomics Institute (IGI) at UC Berkeley. "The current plant transformation ...

Scientists use plasmids as the leading gene delivery technology for a variety of research and clinical applications related to gene therapy. Traditional approaches to plasmid creation often result in ...

Syngene International and Deerfield Discovery and Development Corporation (3DC) have signed an agreement to collaborate to advance therapeutic discovery projects.

However, people rarely sequence the entire plasmid because it’s expensive or it might not ... Berezin: The continued verification of DNA sequences relies on us having good sequencing technology. To ...